Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety - sprookjes - yvandenbroek - TriplyDB

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

http://www.wikidata.org/entity/Q36444510

about

Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer Immunotherapeutic approaches for hepatocellular carcinoma Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Pathogen-driven cancers and emerging immune therapeutic strategies.FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis.MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Management of hepatocellular carcinoma: an overview of major findings from meta-analyses The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors.Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients.A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma.Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin.Downregulation of the H-2Kd gene by siRNA affects the cytotoxicity of murine LAK cells.Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors.Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis.The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Immune-Mediated Therapies for Liver Cancer.Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery.Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors.Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.The Combined Antitumor Effects of 125I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model.Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.Immunomodulation in hepatocellular cancer.AGO1 may influence the prognosis of hepatocellular carcinoma through TGF-β pathway.Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial.

P2860

Q21089654-3800BC7C-A5AB-4A1D-8224-B26B012AB03F Q33779723-B27CBB80-F028-46C9-B430-7FB865DE57B9 Q33875615-6908474E-721A-4A54-BA37-0D08B1AF5AB8 Q34054175-64C85616-9757-4BE4-B1CD-B441B49968BF Q34088194-635B2FCE-DDCF-4FAE-B1C5-A8D07DB369D3 Q34984281-42965A00-B75B-4F38-9C57-5662479B934A Q35032496-4AEDED67-670B-4A31-A929-7A6025F2F234 Q35182896-6638D971-9946-4E2B-9239-55111F689AA9 Q35567765-B88FFC65-E00A-4989-91AA-F095A0559D5F Q36014255-1A6872C5-900B-4586-9D29-9BE3E7EC7560 Q36270334-5B993123-3B82-49EF-BFD0-1820404236B1 Q36502870-CF4CD6DA-71B7-46B4-BB64-0127BAC5C0FF Q36741778-75AFAB33-6ADC-4F15-805F-F9D7F1A58872 Q36821044-E24EC288-CDDC-4F7C-9143-452097B7FF8D Q36865132-4CAF8C2F-0159-4EB9-BC19-3B5FCD325A95 Q37084575-DEA2A01A-E4EF-4BAD-8A83-A70F4E53313C Q37307252-DB083233-BCF0-4DD9-89D6-4AAFB14E61FE Q37367418-54B87B3E-1F0F-4F24-B5FC-99D857EC973B Q37578705-3527A733-BCC4-4528-A9C1-A0E26855C01D Q37701716-BA90B224-B990-4174-8069-5A9EC43B1BD8 Q37718809-9C0FAE24-F61E-4510-92BC-8B4452050CBF Q38835601-E9A73000-A5E0-4703-B0C6-8E92A5428C98 Q39144327-A6CBFF29-EBF2-4E29-8FB6-2F57857A3BC5 Q39208487-51E0FA19-FFE8-4ECF-AFD4-0BDDD1767C3C Q39358916-06520545-733F-4C84-99DD-ED19C330DBC3 Q42677422-12050CDA-884E-4CB2-BA6C-FCA5F95E4216 Q45070547-A6BDBF42-161A-416C-BAC6-76B7BA20DEB4 Q47093613-66D7C81D-2474-40ED-ACF1-24E34FD348CD Q47115641-7195FC92-13A6-4C2E-A2AD-4D0FC9D9F3AC Q49543140-5774EB84-64D4-4D22-979B-DC7A122668E0 Q51633659-E63EAD7F-1C8C-4DDC-8A2A-AE7C202303DD Q52346985-737914E8-D1FB-496F-8460-BB499330C144 Q52729998-CB5CD289-0BF8-452B-8BAA-6BBA5AD56D39 Q52882119-D3C8095B-EE82-403E-8C6C-491147B085F1

P2860

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

http://www.wikidata.org/entity/Q36444510

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@ast

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@en

type

label

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@ast

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@en

prefLabel

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@ast

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@en

P1433

Q36444510-8F1702CF-7905-4242-A509-7AD272420070

P1476

Q36444510-1E8698BF-C0D9-43FC-B343-55C91209655F

P2093

Q36444510-065DE5A0-EE3F-42A1-B712-BF54744B7051

Q36444510-7BEC7F1E-DC71-411C-B712-24F32C6CA759

Q36444510-884DEAF5-F632-47B4-B485-A632A6919050

Q36444510-918F9D26-4F00-4A44-949D-00D593A505D2

Q36444510-9D666B22-867D-4695-AB91-F9F5420CB227

Q36444510-AC05AA40-67C0-411E-9F2F-D7FD892AB40F

P2860

Q36444510-0314D0CC-0AF7-42F0-A694-88686F9C1C6A

Q36444510-068CC1F2-0AE8-4D3A-8D03-D0608830931B

Q36444510-0990073F-6E43-4820-AA04-7F8900D6E23F

Q36444510-11C1DF10-7C14-4455-A9C6-3B824710A268

Q36444510-19F98499-FB8D-4F71-B66A-74523F476C3C

Q36444510-1B2749F1-E65D-4B9B-B619-32B95D83737C

Q36444510-1E164060-CD27-46CA-AD00-6EC25EB3E696

Q36444510-2028DA8B-B348-45D5-B05F-3C7E5EE44A65

Q36444510-29DEFEFD-4210-4DCC-B307-D6C941A13EDC

Q36444510-311365E4-A466-42A6-8A93-59358244FBBD

P2888

Q36444510-2F2F0989-CD3E-45B9-8821-4AC1192C0E7A

P304

Q36444510-6ED57578-DF97-4D57-915B-67EC382D7751

P31

Q36444510-C92D6DE6-9161-489D-9C6E-3B51D568D4FB

P356

Q36444510-7BC1F9CA-F0C3-43A8-81A6-FCEB37E1DCE4

P433

Q36444510-54187A65-B39F-4B0D-88CF-CD91E87F4477

P478

Q36444510-201411B3-5085-461A-B529-6058BDEDAD96

P577

Q36444510-0ADCE9CB-6F80-4B39-A614-29ED4C905B59

P5875

Q36444510-1F187206-D5E9-4098-B863-90B28B847E49

P6179

Q36444510-4F3F9C14-6AD4-4822-BBF1-19D6201E7A89

P698

Q36444510-8C06E788-6CDD-4AB6-8112-8FFCCC7C48E1

P932

Q36444510-B83268AB-B835-4F10-B4D2-F01D79C5DF09

P356

P1433

Experimental Hematology & Oncology

P1476

Cytokine-induced killer (CIK) ...... carcinoma: efficacy and safety

@en

P2093

Hong-Xia Wang

http://www.w3.org/2001/XMLSchema#string

Jian Wang

http://www.w3.org/2001/XMLSchema#string

Lei Tang

http://www.w3.org/2001/XMLSchema#string

Ying-Chun Xu

http://www.w3.org/2001/XMLSchema#string

Yue Ma

http://www.w3.org/2001/XMLSchema#string

Zan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Adoptive T-cell immunotherapy of cancer.

Cytokine-induced NK-like T cells: from bench to bedside.

Targeting insulin-like growth factor axis in hepatocellular carcinoma.

Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).

Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.

The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma.

Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.

P2888

P304

11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2162-3619-1-11

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233847526

http://www.w3.org/2001/XMLSchema#string

P6179

1043269509

http://www.w3.org/2001/XMLSchema#string

P698

23210562

http://www.w3.org/2001/XMLSchema#string

P932

3514101

http://www.w3.org/2001/XMLSchema#string